An Engineered Human Fc-Mannose-Binding-Lectin Captures Circulating Tumor Cells

Area of Science:

• Biotechnology
• Immunology
• Oncology

Background:

• Circulating tumor cells (CTCs) hold potential for cancer diagnostics and therapeutics.
• Current methods for CTC isolation are limited by the lack of broad-spectrum, specific binding reagents.

Purpose of the Study:

• To evaluate the efficacy of engineered Fc-mannose binding lectin (FcMBL) for broad-spectrum capture of circulating tumor cells.
• To develop a novel method for high-efficiency isolation of CTCs.

Main Methods:

• Utilizing FcMBL-coated magnetic beads to capture tumor cells.
• Comparing FcMBL binding to cancer cells versus normal cells.
• Assessing FcMBL capture efficiency across various cancer cell types.
• Testing FcMBL capture of CTCs from blood samples of tumor-bearing mice.

Main Results:

• FcMBL demonstrated broad-spectrum binding and capture of diverse tumor cells, including types poorly recognized by anti-EpCAM antibodies.
• Capture efficiency exceeded 90% for seven different cancer cell types.
• FcMBL preferentially bound to human and mouse breast cancer cells compared to normal breast epithelium.
• FcMBL-coated magnetic beads successfully captured CTCs from the blood of mice with metastatic tumors.

Conclusions:

• Engineered FcMBL offers a highly efficient and broad-spectrum approach for capturing circulating tumor cells.
• This FcMBL-based technology represents a significant advancement for CTC isolation, with potential applications in cancer diagnosis and therapy.
• FcMBL targets conserved tumor-specific surface markers, facilitating capture across diverse cancer types and metastatic stages.